ATS 2020 Advance Program

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM B9 2020 VISION OF TB Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Nursing; Pulmonary Rehabilitation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology 9:15 a.m. - 11:15 a.m. Target Audience Pulmonary, infectious disease, public health, other clinicians and nurses; basic, clinical and translational investigators; infection control and occupational health practitioners; oncologists; practitioners in pulmonary rehabilitation. Objectives At the conclusion of this session, the participant will be able to: • learn new findings about tuberculosis (TB) pathogenesis and airborne transmission; • improve the quality of life of patients with post-TB lung disease; • increase awareness of the risk of reactivation of TB during the use of PD-1 (checkpoint) inhibitors now commonly used in cancer immunotherapy. This session will present exciting new data about how Mycobacterium tuberculosis gains access to cells and is transmitted by the airborne route. Attendees will learn about a new risk factor for the reactivation of TB among cancer patients. Lung disease after the successful treatment of TB is common, and attendees will learn what can be done to manage ‘post-TB lung disease.’ Attendees will also learn about how to protect themselves from TB. Chairing: P.A. Lobue, MD, Atlanta, GA K.P. Fennelly, MD, MPH, ATSF, Bethesda, MD J.M. Keane, MD, Dublin, Ireland 9:15 The Cellular In’s and Out’s of M. Tuberculosis M. Shiloh, MD, PhD, Dallas, TX 9:35 Airborne TB: A New View from Mask Aerosol Sampling C. Williams, MD, PhD, Leicester, United Kingdom 9:55 Risk of TB with Checkpoint Inhibitors in Cancer Immunotherapy D. Barber, PhD, Bethesda, MD 10:15 Pulmonary Rehabilitation for Post-TB Lung Disease B. Kirenga, MBChB, MMED, Kampala, Uganda 10:35 New CDC Recommendations on TB Testing and Treatment of Health Care Workers P.A. Lobue, MD, Atlanta, GA 10:55 Panel Discussion K.P. Fennelly, MD, MPH, ATSF, Bethesda, MD BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM B10 EARLY PULMONARY COMPLICATIONS OF PEDIATRIC STEM CELL TRANSPLANT: UPDATE FROM NIH WORKSHOP Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Pulmonary Infections and Tuberculosis 9:15 a.m. - 11:15 a.m. Target Audience Pediatric and adult pulmonologists, fellows, residents and medical students, basic researchers in lung injury Objectives At the conclusion of this session, the participant will be able to: • understand the many factors involved in early lung injury post hematopoietic stem cell transplantation; • understand the gaps in knowledge in early lung injury post hematopoietic stem cell transplantation; • define future direction in research and treatment of early lung disease post hematopoietic stem cell transplantation. Pediatric hematopoietic stem cell transplantation (HCT) is performed for malignant and non-malignant conditions. Pulmonary complications constitute the ATS 2020 • Philadelphia, PA 72 MONDAY • MAY 18